Abstracts tagged "Health Care"

Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
Abstract Number: 0785 • ACR Convergence 2023
Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie M. Bartels³, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to…
Abstract Number: 2257 • ACR Convergence 2023
Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)
Konstantinos Parperis¹ and Bikash Bhattarai², ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Valleywisehealth, Phoenix, AZ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease associated with an increased risk of cardiovascular complications, including acute coronary syndrome (ACS). However, there…
Abstract Number: 0994 • ACR Convergence 2023
Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias
Aviya Lanis, Natalie Rosenwasser and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Burnout, a syndrome of emotional exhaustion and depersonalization, adversely impacts healthcare and results in mood disturbances, poor patient and provider satisfaction and high turnover.…
Abstract Number: 2304 • ACR Convergence 2023
Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study
Joshua Reed, Anam Nazir, Khalid Alghamdi and Catherine Ivory, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is variable in clinical presentation and has fluctuating disease severity. Health outcomes in SLE have been linked to both genetic…
Abstract Number: 1015 • ACR Convergence 2023
Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives
Dana Wiens¹, David Robinson¹, Irene Smolik¹, Cheryl Barnabe², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…
Abstract Number: 1031 • ACR Convergence 2023
Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System
Joseph Kim¹, Song Zhang² and Elizabeth Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality, particularly if RA is poorly controlled. The effects of socioeconomic deprivation have not been…
Abstract Number: 1082 • ACR Convergence 2023
Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic
Nicola Jackson¹, Meg James², Kim Nguyen³, Priyanka Vashisht² and Avis Ware⁴, ¹University of Cincinnati, Rheumatology, Blue Ash, OH, ²University of Cincinnati Medical Center, Cincinnati, OH, ³University of Cincinnati Medical Center, Loveland, OH, ⁴University of Cincinnati College of Medicine, Loveland, OH
Background/Purpose: Patient no-shows and late cancellations, defined as less than 24 hours from the visit, reduce operational efficiency, revenue generation, and lead to negative clinical…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 0125 • ACR Convergence 2023
Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis
snehin Rajkumar¹ and Ram Singh², ¹University of California Los Angeles, Irvine, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with lupus nephritis may die of active systemic lupus erythematosus (SLE) disease, end-stage renal disease (ESRD) and its complications as well as of…
Abstract Number: 1231 • ACR Convergence 2023
Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis
Y. Ingrid Goh¹, Kayla Baker¹, Audrey Bell-Peter¹, Vanessa Carbone¹, Brian Feldman¹, Luana Flores Pereira¹, Jayne MacMahon¹, Valerio Maniscalco¹, Jo-Anne Marcuz¹, Greta Mastrangelo², Tanya Slater¹, Kristi Whitney¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: High levels of emotional distress have been reported in children with juvenile myositis (JM). Inadequate recognition of mental health concerns by healthcare providers (HCPs)…
Abstract Number: 0158 • ACR Convergence 2023
Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes
Lindsay Jacobsohn¹, Emma Kersey¹, Jing Li¹, Catherine Nasrallah¹, Cherish Wilson², Cammie Young³, Cammie Young³, Alicia Hamblin¹, Jinoos Yazdany¹ and Gabriela Schmajuk², ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA
Background/Purpose: We developed an electronic health record (EHR)-based patient-facing sidecar dashboard application to display RA outcomes, including disease activity, functional status, and pain scores over…
Abstract Number: 1578 • ACR Convergence 2023
Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis
Alejandra Espinosa-Orantes¹, David Vera-Bustamante², Jessica Roldan Ortega³, Maria Mejia-Avila⁴, Jose Raul Molina⁵, Evelyn Aranda Cano⁵, Adriana Miguel-Alvarez⁵, Ismael Valenzuela⁵, Viridiana Del Río-Guerrero⁶, Paloma Rodriguez⁵, Mauricio Mora-Ramirez⁵, Nilda Espinola-Zavaleta⁴, Luis H Silveira-torre⁶, Angélica Vargas Guerrero⁷ and Laura A Martínez-Martínez⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, ⁴Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁶Instituto Nacional de Cardiología, Mexico City, Mexico, ⁷Instituto Nacional de Cardiología, Mexico City, Mexico, ⁸Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Brigitte Michelsen¹, Mikkel Østergaard², Michael Nissen³, Adrian Ciurea⁴, Burkhard Moeller⁵, Lykke Ørnbjerg⁶, Jakub Zavada⁷, Bente Glintborg⁸, Alan MacDonald⁹, Karin Laas¹⁰, Dan Nordstrom¹¹, Bjorn Gudbjornsson¹², Florenzo Iannone¹³, Pasoon Hellamand¹⁴, Tore Kvien¹⁵, Ana Maria Rodrigues¹⁶, Catalin Codreanu¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Johan Karlsson Wallman²⁰, Jiri Vencovsky²¹, Anne Gitte Loft²², Maureen Heddle²³, Sigrid Vorobjov²⁴, Anna-Mari Hokkanen²⁵, Gerdur Maria Grondal²⁶, Marco Sebastiani²⁷, Marleen van de Sande²⁸, Eirik Kristianslund²⁹, Maria Jose Santos³⁰, Corina Mogosan³¹, Matija Tomsic³², Jose Federico Diaz-Gonzalez³³, Daniela Di Giuseppe³⁴ and Merete Hetland⁶, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ³Geneva University Hospitals, Geneva, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁹NHS Grampian, Aberdeen, United Kingdom, ¹⁰Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ¹⁷Center for Rheumatic Diseases, Bucharest, Romania, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lund University and Skåne University Hospital, Lund, Sweden, ²¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²²Aarhus University, Horsens, Denmark, ²³Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ²⁴National Institute for Health Development, Tallinn, Estonia, ²⁵Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁶Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²⁷Azienda Policlinico di Modena, Modena, Italy, ²⁸Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²⁹Diakonhjemmet Hospital, Oslo, Norway, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹University of Medicine and Pharmacy, Bucharest, Romania, ³²University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, ³³Hospital Universitario de Canarias, La Laguna, Spain, ³⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Shivani Garg¹, Giancarlo Valiente², Lexie Kolton³, Callie Saric³, Betty Chewning⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].